Statins and their use in preventing carotid disease

Statins impair survival of primary human mesenchymal progenitor cells via mevalonate depletion, NF-κB signaling, and Bnip3

Circulating progenitor cells of bone marrow origin have been implicated in transplant cardiac allograft vasculopathy (CAV) and cardiac fibrosis. HMG-CoA reductase inhibitors, called "statins," have been shown to impair the progression of CAV and improve patient survival. We examined the in vitro effects of three HMG-CoA reductase inhibitors atorvastatin, simvastatin, and pravastatin on the viability of MSCs and expression of nuclear factor kappa B (NF-κB). Mesenchymal stem cells (MSCs) isolated from human patients were treated with atorvastatin, simvastatin, and pravastatin at 0.1, 1.0, or 10 μM ± mevalonate. Human MSC treatment with 1 and 10 μM simvastatin or atorvastatin resulted in progressively reduced cell viability, which was associated with a decline in NF-κB p65. Viability was rescued by co-incubation with mevalonate or by pretreatment with Inhibitor of nuclear factor kappa-B kinase subunit beta (Iκκ-β). Pravastatin did not affect MSC viability or NF-κB expression. Mevalonate depletion through HMG-CoA reductase inhibition impairs the viability of primary human MSC through down-regulating NF-κB.

Carotid disease in acute ischemic stroke patients of northern Israel

BACKGROUND

Carotid disease complicated by thrombosis or embolism is a frequent cause of acute ischemic stroke. The aim of the study was to determine factors associated with carotid disease in patients suffering from acute ischemic stroke in northern Israel.

METHODS

Participants were 1378 acute ischemic stroke patients, including 671 patients with and 707 patients without carotid plaques, as defined by cervical ultrasound.

RESULTS

Logistic regression analysis of possible predictors revealed that age, male gender, diabetes, hyperlipidemia, and smoking were independent predictors for the presence of carotid plaque. Male gender was independently associated with the increased prevalence of carotid stenosis of 50% or more, as well as with symptomatic carotid plaques. Age was found to be the only independent factor influencing the extent (bilateral vs unilateral) of carotid disease among acute ischemic stroke patients in northern Israel. Although ethnicity was initially found to have an influence on the prevalence of carotid plaques (higher among Jews than Arabs), no such influence was found after logistic regression.

CONCLUSION

Our findings emphasize that demographic characteristics (age, gender) and vascular risk factors (diabetes, smoking and hyperlipidemia) rather than ethnic disparities are important determinants of carotid disease in acute ischemic stroke patients in northern Israel.

Statins and noncardiac vascular disease

PURPOSE OF REVIEW

To discuss the beneficial effects of statin treatment in patients with peripheral arterial disease (PAD), abdominal aortic aneurysms (AAAs), atherosclerotic renal artery stenosis (ARAS) and carotid artery disease.

RECENT FINDINGS

Evidence suggests that statins may reduce the progression (or even reverse the development) of carotid artery stenosis and AAAs. Statins also improve several indices (e.g. serum creatinine) and preserve renal function in ARAS. In patients with PAD, statins are associated with improved claudication distance and time, reduced cardiovascular events, and improved graft patency rates should these patients undergo surgery. Finally, statins are associated with improved perioperative and long-term morbidity and mortality rates in all vascular patients whether they undergo surgery or endovascular procedures.

SUMMARY

Routine statin treatment should be implemented for all vascular patients to ensure a reduced progression of their disease, as well as a reduction in cardiovascular events.